NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/sarepta-lawsuit-submi ...

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety and revenue outlook of its gene therapy ELEVIDYS, which is intended to treat Duchenne muscular dystrophy [1][3]. Company Overview - Sarepta Therapeutics is a biopharmaceutical company focused on developing gene therapies, specifically ELEVIDYS, for treating Duchenne muscular dystrophy [3]. Allegations and Misleading Statements - The lawsuit claims that Sarepta made materially false and misleading statements about ELEVIDYS, leading investors to believe it was a safe therapy with no hindrances to broader application approval [3]. - Specific allegations include: - ELEVIDYS posed significant safety risks to patients [3]. - Trial protocols failed to detect severe side effects [3]. - Adverse events would lead to halted recruitment and dosing in trials, attracting regulatory scrutiny [3]. - Positive statements made by the company lacked a reasonable basis due to undisclosed material adverse facts [3]. Stock Price Impact - Following a safety update on March 18, 2025, where a patient died after treatment with ELEVIDYS, Sarepta's stock price fell by $27.81 per share, or 27.44%, closing at $73.54 [4]. - On April 4, 2025, after the company disclosed regulatory scrutiny and halted recruitment, the stock price fell by $4.18 per share, or 7.13%, closing at $54.43 [4]. - A second patient death was reported on June 15, 2025, leading to a significant drop of $15.24 per share, or 42.12%, closing at $20.91 [4]. - Following an FDA Safety Communication on June 24, 2025, the stock price fell by $1.52 per share, or 8.01%, closing at $17.46 [4].

Core Viewpoint - A securities class-action lawsuit has been initiated against Sarepta Therapeutics due to safety concerns and regulatory setbacks related to its gene therapy, ELEVIDYS, alleging that the company misled investors about the treatment's safety and efficacy [1]. Company Developments - The lawsuit claims that Sarepta misrepresented ELEVIDYS as a safe and effective treatment with a clear path to regulatory approval, which has led to significant investor losses [1]. - The European Medicines Agency (EMA) rejected ELEVIDYS on July 24, 2025, after a trial involving 125 children showed no significant improvement in movement compared to a placebo, severely impacting Sarepta's European market expansion plans [3]. - The timeline of disclosures indicates that Sarepta's stock price has faced multiple declines due to safety and regulatory news, including a patient death in an ELEVIDYS trial reported on March 18, 2025, and a subsequent investigation by EU authorities [6]. Legal and Investigative Actions - Hagens Berman, a national shareholder rights firm, is investigating claims on behalf of investors who suffered substantial losses and is encouraging individuals with relevant information to come forward [4][5]. - The firm has set a deadline of August 25, 2025, for investors to be considered as Lead Plaintiff in the lawsuit, which covers the class period from June 22, 2023, to June 24, 2025 [2].

NEW YORK, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/sarepta-lawsuit-submi ...

NEW YORK, Aug. 22, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the "Class Period"), of the important August 25, 2025 lead plaintiff deadline.So What: If you purchased Sarepta Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ar ...

SAN DIEGO, Aug. 22, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025, inclusive (the "Class Period"), have until this Monday, August 25, 2025 to seek appointment as lead plaintiff of the Sarepta class action lawsuit.  Captioned Dolgicer v. Sarepta Therapeutics, Inc., No. 25-cv-05317 (S.D.N.Y.), the Sarepta class action lawsuit charges Sarepta and certain of Sarepta's to ...

SAN FRANCISCO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- A securities class-action lawsuit is underway against Sarepta Therapeutics (NASDAQ: SRPT), triggered by a series of safety concerns and regulatory setbacks for its gene therapy, ELEVIDYS. The lawsuit alleges that Sarepta misled investors by presenting ELEVIDYS as a safe and effective treatment with a clear path to broader regulatory approval. The deadline for investors with losses to be considered by the court to serve as Lead Plaintiff is August 25, 2025. Ha ...

SAN DIEGO, Aug. 21, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025, inclusive (the "Class Period"), have until Monday, August 25, 2025 to seek appointment as lead plaintiff of the Sarepta class action lawsuit. Captioned Dolgicer v. Sarepta Therapeutics, Inc., No. 25-cv-05317 (S.D.N.Y.), the Sarepta class action lawsuit charges Sarepta as well as certai ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sarepta Therapeutics, Inc. regarding a class action lawsuit related to misleading statements about the safety and efficacy of its gene therapy product, ELEVIDYS [1][3]. Summary by Relevant Sections Class Action Details - The class period for the lawsuit is from June 22, 2023, to June 24, 2025 [3]. - Shareholders who purchased shares during this period are encouraged to contact the firm for potential lead plaintiff appointment, although this is not required for recovery [1][4]. Allegations Against Sarepta Therapeutics - The complaint alleges that Sarepta Therapeutics made materially false and/or misleading statements regarding ELEVIDYS, a gene therapy for Duchenne muscular dystrophy [3]. - Specific allegations include: - ELEVIDYS poses significant safety risks to patients [3]. - The trial protocols failed to detect severe side effects [3]. - Adverse events from ELEVIDYS treatment could lead to halting recruitment and dosing in trials, attracting regulatory scrutiny [3]. - The misleading statements resulted in a lack of reasonable basis for the company's positive outlook on the therapy [3]. Next Steps for Shareholders - Shareholders are advised to register for the class action by August 25, 2025, to participate in the case [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software [4]. About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

SAN FRANCISCO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- A securities class-action lawsuit is underway against Sarepta Therapeutics (NASDAQ: SRPT), triggered by a series of safety concerns and regulatory setbacks for its gene therapy, ELEVIDYS. The lawsuit alleges that Sarepta misled investors by presenting ELEVIDYS as a safe and effective treatment with a clear path to broader regulatory approval. The deadline for investors with losses to be considered by the court to serve as Lead Plaintiff is August 25, 2025. Ha ...